BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 10726794)

  • 21. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
    Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension.
    Diestelhorst M; Larsson LI;
    Br J Ophthalmol; 2004 Feb; 88(2):199-203. PubMed ID: 14736774
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including pseudoexfoliation glaucoma or ocular hypertension. 6 month data.
    Nordmann JP; Mertz B; Yannoulis NC; Schwenninger C; Kapik B; Shams N;
    Am J Ophthalmol; 2002 Jan; 133(1):1-10. PubMed ID: 11755834
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A 6-month randomized clinical trial of bimatoprost 0.03% versus the association of timolol 0.5% and latanoprost 0.005% in glaucomatous patients.
    Manni G; Centofanti M; Parravano M; Oddone F; Bucci MG
    Graefes Arch Clin Exp Ophthalmol; 2004 Sep; 242(9):767-70. PubMed ID: 15241611
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peak pressures: crossover study of timolol and latanoprost.
    Sihota R; Saxena R; Agarwal HC; Pandey RM; Gulati V
    Eur J Ophthalmol; 2003 Jul; 13(6):546-52. PubMed ID: 12948313
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and side effects of latanoprost monotherapy compared to adding dorzolamide to timolol in patients with glaucoma and ocular hypertension--a three-month randomised study. Spanish Latanoprost Study Group.
    García Sanchez J
    Eur J Ophthalmol; 2000; 10(3):198-204. PubMed ID: 11071026
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma.
    Mastropasqua L; Carpineto P; Ciancaglini M; Gallenga PE
    Ophthalmology; 1999 Mar; 106(3):550-5. PubMed ID: 10080213
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Additive IOP-reducing effect of latanoprost in patients insufficiently controlled on timolol.
    Bron AM; Denis P; Nordmann JP; Rouland JF; Sellem E; Johansson M
    Acta Ophthalmol Scand; 2001 Jun; 79(3):289-93. PubMed ID: 11401641
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [A comparison between latanoprost and timolol in treatment of patients with primary open-angle glaucoma and ocular hypertension].
    Peng D; Li S; Li M; Shao H; Sun X; Sheng Y; Yu K; Fu P; Guo W; Meng F; Xu C; Zhu Z
    Zhonghua Yan Ke Za Zhi; 2000 Jul; 36(4):285-8. PubMed ID: 11853616
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the additive intraocular pressure-lowering effect of latanoprost and dorzolamide when added to timolol in patients with open-angle glaucoma or ocular hypertension: a randomized, open-label, multicenter study in Greece.
    Petounis A; Mylopoulos N; Kandarakis A; Andreanos D; Dimitrakoulias N
    J Glaucoma; 2001 Aug; 10(4):316-24. PubMed ID: 11558817
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Latanoprost treatment for glaucoma: effects of treating for 1 year and of switching from timolol. United States Latanoprost Study Group.
    Camras CB; Wax MB; Ritch R; Weinreb R; Robin AL; Higginbotham EJ; Lustgarten J; Stewart WC; Sherwood M; Krupin T; Wilensky J; Cioffi GA; Katz LJ; Schumer RA; Kaufman PL; Minckler D; Zimmerman T; Stjernschantz J
    Am J Ophthalmol; 1998 Sep; 126(3):390-9. PubMed ID: 9744372
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Short-term effect of latanoprost and timolol eye drops on tear fluid and the ocular surface in patients with primary open-angle glaucoma and ocular hypertension.
    Thygesen J; Aaen K; Theodorsen F; Kessing SV; Prause JU
    Acta Ophthalmol Scand; 2000 Feb; 78(1):37-44. PubMed ID: 10726786
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components.
    Diestelhorst M; Larsson LI;
    Ophthalmology; 2006 Jan; 113(1):70-6. PubMed ID: 16263174
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Latanoprost versus timolol gel-forming solution once daily in primary open-angle glaucoma or ocular hypertension.
    Harasymowycz P; Hutnik CM; Nicolela M; Stewart WC
    Can J Ophthalmol; 2007 Feb; 42(1):75-81. PubMed ID: 17361245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect on intraocular pressure during 24 hours after repeated administration of the fixed combination of latanoprost 0.005% and timolol 0.5% in patients with ocular hypertension.
    Larsson LI
    J Glaucoma; 2001 Apr; 10(2):109-14. PubMed ID: 11316092
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial.
    Walters TR; DuBiner HB; Carpenter SP; Khan B; VanDenburgh AM;
    Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S26-35. PubMed ID: 15016559
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intraocular pressure-lowering effects of latanoprost monotherapy versus latanoprost or pilocarpine in combination with timolol: a randomized, observer-masked multicenter study in patients with open-angle glaucoma. Italian Latanoprost Study Group.
    Bucci MG
    J Glaucoma; 1999 Feb; 8(1):24-30. PubMed ID: 10084271
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 24-hour efficacy of the bimatoprost-timolol fixed combination versus latanoprost as first choice therapy in subjects with high-pressure exfoliation syndrome and glaucoma.
    Konstas AG; Holló G; Mikropoulos DG; Haidich AB; Dimopoulos AT; Empeslidis T; Teus MA; Ritch R
    Br J Ophthalmol; 2013 Jul; 97(7):857-61. PubMed ID: 23686322
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers: tolerance and peak intraocular pressure lowering.
    Simmons ST; Earl ML;
    Ophthalmology; 2002 Feb; 109(2):307-14; discussion 314-5. PubMed ID: 11825814
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Latanoprost versus combined therapy with timolol plus dorzolamide: IOP-lowering effect in open-angle glaucoma.
    Polo V; Larrosa JM; Gomez ML; Pablo L; Honrubia FM
    Acta Ophthalmol Scand; 2001 Feb; 79(1):6-9. PubMed ID: 11167277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.